{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARGX",
    "company_name": "argenx",
    "data_source": "argenx 2026 JPM Corporate Presentation",
    "extraction_date": "2026-02-04"
  },
  "company": {
    "name": "argenx",
    "ticker": "ARGX",
    "exchange": "NASDAQ / Euronext Brussels",
    "headquarters": "Breda, Netherlands",
    "website": "https://argenx.com",
    "one_liner": "Commercial-stage immunology leader with $4.2B VYVGART franchise, first-in-class FcRn platform, and 10 clinical-stage molecules targeting 50K patients by 2030"
  },
  "investment_thesis_summary": {
    "core_thesis": "argenx has built the leading FcRn inhibitor franchise with VYVGART generating $4.2B in 2025 (90% YoY growth) and achieving first-year operating profitability. The company's Vision 2030 targets 50K patients on treatment, 10 labeled indications, and 5 new molecules in Phase 3, supported by 6 registrational readouts over the next 24 months.",
    "key_value_drivers": [
      "VYVGART $4.2B FY2025 revenue with 90% YoY growth, first year of operating profitability",
      "6 Phase 3 readouts over 24 months: Ocular MG (1Q26), Myositis (3Q26), ITP (4Q26), MMN (4Q26), CIDP (2H27), Sjögren's (2H27)",
      "MG TAM expanding from 17K to 60K US patients by 2030",
      "Second pillar with empasiprubart (C2 complement) - MMN Phase 3 readout 4Q 2026"
    ]
  },
  "investment_analysis": {
    "bull_case": [
      "VYVGART already $4.2B with 90% growth; trajectory toward $10B+ peak across indications",
      "First mover advantage in FcRn with broadest label and real-world evidence (~19K patients treated)",
      "#1 prescribed biologic in MG; blockbuster status in CIDP as of 3Q 2025",
      "6 Phase 3 readouts over 24 months significantly de-risk pipeline",
      "Multiple mechanisms (FcRn, C2, MuSK, IgA) diversify beyond single target",
      "Operating profitability achieved in 2025; self-funding growth",
      "60K addressable MG patients by 2030 (3.5x expansion from launch)"
    ],
    "bear_case": [
      "FcRn competition intensifying: UCB RYSTIGGO approved, J&J nipocalimab in Phase 3",
      "High valuation requires continued execution across multiple programs",
      "Phase 3 trials in heterogeneous diseases (Myositis, Sjögren's) carry execution risk",
      "Complement space has established players (Alexion/AstraZeneca C5 inhibitors)",
      "Large commercial organization requires continued investment"
    ],
    "key_debates": [
      {
        "question": "Can argenx maintain FcRn leadership as competition enters?",
        "bull_view": "First mover with most experience, broadest program, and next-gen molecules (ARGX-213 monthly dosing)",
        "bear_view": "FcRn is validated mechanism; competitors may erode share with differentiated profiles",
        "what_resolves_it": "Market share trends post-RYSTIGGO launch; ARGX-213 Phase 3 data"
      },
      {
        "question": "Will empasiprubart establish a second commercial pillar?",
        "bull_view": "First-in-class C2 sweeper with differentiated mechanism; >$1B MMN market",
        "bear_view": "Novel mechanism without precedent; head-to-head vs IVIg is challenging",
        "what_resolves_it": "MMN Phase 3 EMPASSION readout 4Q 2026"
      }
    ]
  },
  "pipeline_summary": {
    "total_programs": 10,
    "clinical_stage": 10,
    "programs": [
      {
        "asset": "efgartigimod (VYVGART)",
        "target": "FcRn",
        "stage": "Approved + Phase 3",
        "indications": "gMG (approved), CIDP (approved), Ocular MG, ITP, Myositis, Sjögren's",
        "ownership": "Wholly-owned",
        "next_catalyst": "Ocular MG Phase 3 - 1Q 2026"
      },
      {
        "asset": "empasiprubart",
        "target": "C2 (Complement)",
        "stage": "Phase 3",
        "indications": "MMN, CIDP",
        "ownership": "Wholly-owned",
        "next_catalyst": "MMN Phase 3 - 4Q 2026"
      },
      {
        "asset": "adimanebart",
        "target": "MuSK",
        "stage": "Registrational",
        "indications": "CMS, ALS, SMA",
        "ownership": "Wholly-owned",
        "next_catalyst": "CMS registrational data"
      },
      {
        "asset": "ARGX-213",
        "target": "FcRn (sustained)",
        "stage": "Phase 3 ready",
        "indications": "15+ potential indications",
        "ownership": "Wholly-owned",
        "next_catalyst": "Phase 3 initiation"
      },
      {
        "asset": "ARGX-121",
        "target": "IgA",
        "stage": "Phase 1",
        "indications": "IgA Nephropathy",
        "ownership": "Wholly-owned",
        "next_catalyst": "Phase 1 data"
      },
      {
        "asset": "ARGX-109",
        "target": "IL-6",
        "stage": "PoC",
        "indications": "Multiple autoimmune",
        "ownership": "Wholly-owned",
        "next_catalyst": "PoC data"
      },
      {
        "asset": "ARGX-118",
        "target": "Galectin-10",
        "stage": "Phase 1 (2026)",
        "indications": "TBD",
        "ownership": "Wholly-owned",
        "next_catalyst": "Phase 1 initiation 2026"
      }
    ]
  },
  "platform": {
    "name": "Antibody Engineering Platform",
    "description": "argenx leverages proprietary Fc modifications (Fc-ABDEG) and llama-derived single domain antibodies (VHH) to create differentiated therapeutics. The innovation engine targets 1 IND per year with 25 active IIP programs spanning neurology, rheumatology, renal, and dermatology."
  },
  "financials": {
    "fy_2025_revenue": "$4,151M product net sales",
    "yoy_growth": "90% (ex-FX)",
    "q4_2025_revenue": "$1,286M",
    "profitability": "First year of operating profitability in 2025",
    "cash_runway": "Self-funding with profitability"
  },
  "commercial_performance": {
    "global_patients": "~19,000 on VYVGART globally",
    "us_prescribers": ">4,700 prescribers",
    "prescriber_growth": "20% YoY increase in new prescribers",
    "mg_position": "#1 prescribed biologic in MG",
    "cidp_status": "Blockbuster status as of 3Q 2025"
  },
  "market_opportunity": {
    "myasthenia_gravis": {
      "us_addressable_at_launch": "17K patients",
      "us_addressable_2030": "60K patients",
      "expansion_drivers": "Seronegative (+11K), Ocular (+7K), biologics share growth (+25K)"
    },
    "cidp": {
      "us_addressable_at_launch": "12K patients",
      "us_total_diagnosed": "42K patients"
    },
    "autoimmune_myositis": {
      "us_prevalence": "70K patients (DM 40K, IMNM 20K, PM 10K)"
    },
    "sjogrens_disease": {
      "us_prevalence": "330K total, 100K moderate-to-severe"
    },
    "mmn": {
      "global_patients": "12K across key markets",
      "market_size": "$750-800M today, >$1B by 2030"
    }
  },
  "catalysts_2026": [
    {
      "event": "Ocular MG Phase 3 readout",
      "timing": "1Q 2026",
      "significance": "First and only Ocular MG development; +7K patients"
    },
    {
      "event": "Myositis Phase 3 readout (ALKIVIA)",
      "timing": "3Q 2026",
      "significance": "Rheumatology expansion; 70K US patients"
    },
    {
      "event": "ITP Phase 3 readout (ADVANCE-NEXT)",
      "timing": "4Q 2026",
      "significance": "Hematology market expansion"
    },
    {
      "event": "Empasiprubart MMN Phase 3 (EMPASSION)",
      "timing": "4Q 2026",
      "significance": "First Phase 3 for second molecule; >$1B market"
    },
    {
      "event": "Seronegative MG approval decision",
      "timing": "By end of 2026",
      "significance": "Broadest MG label; +11K patients"
    }
  ]
}
